Ten-day decitabine vs "3+7" in patients with AML aged ≥60 years: long-term results of the randomized phase 3 EORTC trial AML21.
Lübbert M, Wijermans PW, Kicinski M, Chantepie S, Van der Velden WJFM, Noppeney R, Griškevičius L, Neubauer A, Crysandt M, Vrhovac R, Luppi M, Fuhrmann S, Audisio E, Candoni A, Legrand O, Foà R, Gaidano G, van Lammeren-Venema D, Posthuma EFM, Hoogendoorn M, Giraut A, Antunes S, Stevens-Kroef M, Jansen JH, de Graaf AO, Efficace F, Ammatuna E, Levesque Q, Wäsch R, Becker H, Blijlevens N, Dührsen U, Baron F, Suciu S, Venditti A, Huls G; EORTC Leukemia Group, Italian Group for Adult Hematologic Diseases, and German MDS Study Group.
Lübbert M, et al.
Blood Neoplasia. 2026 May 13;3(3):100246. doi: 10.1016/j.bneo.2026.100246. eCollection 2026 Aug.
Blood Neoplasia. 2026.
PMID: 42436879
Free PMC article.